Otsuka Energizes IgA Nephropathy Space with New Phase 3 Voyxact Data

Otsuka's Voyxact Shows Kidney Function Stabilization in Phase 3 IgAN Study

Otsuka Pharmaceuticals' APRIL inhibitor, Voyxact, demonstrated stabilization of kidney function decline in interim Phase 3 VISIONARY trial data for IgA nephropathy (IgAN). Patients on Voyxact showed a 0.7 mL/min/1.73 m2 increase in estimated glomerular filtration rate (eGFR) at 12 months, meeting the professional standard to slow decline to a normal physiological rate. This contrasts with a 4.8 mL/min/1.73 m2 decline in placebo comparators. These findings are crucial for supporting the conversion of Voyxact's November 2025 accelerated FDA approval for proteinuria reduction to full approval, with Otsuka already initiating a rolling biologics application. The data also validates the APRIL pathway and has positive implications for competitors.

• The Phase 3 VISIONARY trial revealed that Voyxact led to a 0.7 mL/min/1.73 m2 increase in estimated glomerular filtration rate (eGFR) over 12 months in IgAN patients. This outcome is considered by Otsuka to meet the professional standard for slowing kidney function decline to a normal physiological rate, contrasting sharply with a 4.8 mL/min/1.73 m2 decline observed in the placebo group. This clear demonstration of kidney benefit in a global, placebo-controlled study is a significant validation for the APRIL pathway in IgAN treatment.
• These interim Phase 3 results are crucial for Otsuka's regulatory strategy, aiming to convert Voyxact's accelerated FDA approval, granted in November 2025 for proteinuria reduction in IgAN, into full approval. The company has already commenced a rolling biologics application based on these positive findings. This progression underscores the potential for Voyxact to become a fully approved treatment option, building on its initial conditional approval.
• The positive data for Voyxact not only strengthens Otsuka's position but also has significant readthroughs for other companies developing APRIL inhibitors, such as Vertex Pharmaceuticals with povetacicept and Vera Therapeutics with atacicept. Analysts suggest the data reinforces the link between proteinuria reduction and eGFR benefits, potentially solidifying accelerated approval paths for similar assets. However, it also fuels the ongoing debate regarding the superiority of dual BAFF/APRIL inhibition versus an APRIL-only approach, highlighting the evolving understanding of IgAN pathology.

Voyxact's VISIONARY Data: A Path to Full Approval in IgAN

The VISIONARY trial represents the largest IgA nephropathy study to date, enrolling 510 patients across 31 countries in a phase 3, double-blind, placebo-controlled evaluation of sibeprenlimab. This selective APRIL inhibitor targets pathogenic galactose-deficient IgA1 production and immune complex formation through subcutaneous administration of 400 mg once every 4 weeks for 26 doses. The study population had a median age of 42 years, with 97.8% using renin-angiotensin system inhibitors and mean baseline proteinuria of 2.1 g/day, establishing its relevance to real-world IgAN management.

Recent observational studies have demonstrated the efficacy of repurposed therapies in IgAN. A 2025 dapagliflozin study of 84 patients with biopsy-confirmed disease showed significant improvement in eGFR slope from -1.92 to -0.69 ml/min per 1.73 m²/year over approximately 3 years of observation. Complementing this, a telitacicept study involving 24 patients demonstrated significant proteinuria reduction at 12 and 24 weeks across all treatment groups, achieving complete remission in 16.7% and partial remission in 62.5% of patients, with generally well-tolerated safety profiles when used as monotherapy or combined with corticosteroids.

Comprehensive meta-analyses published in 2025-2026 have provided crucial comparative effectiveness data across drug classes. Analysis of 14 randomized trials revealed that B-cell modulating agents achieved the most favorable eGFR slope improvement of 4.3 mL/min/1.73 m²/year (-73% relative effect), while corticosteroids demonstrated the greatest proteinuria reduction at -51%. However, corticosteroids carried the highest adverse event risk (RR 3.28), whereas complement pathway inhibitors showed superior eGFR preservation (+5.8 mL/min/1.73 m²/year) with more favorable safety profiles. These findings support the evolving precision medicine approach outlined in KDIGO 2025 guidelines, which emphasize stricter proteinuria targets (<0.5 g/day, ideally <0.3 g/day) and multitargeted therapeutic strategies.

Unpacking the VISIONARY Trial Design and Primary Endpoints

The IgA nephropathy clinical trial landscape spans over two decades, with recent phase 3 studies representing the largest and most sophisticated investigations to date. The VISIONARY trial stands out as the largest IgA nephropathy trial ever conducted, enrolling 510 patients across 31 countries, while other landmark studies like NefIgArd have established new standards for trial design and endpoint selection in this indication.

Voyxact's eGFR Data: A New Standard for IgAN Kidney Preservation

The latest interim Phase 3 data for Otsuka's Voyxact in IgA nephropathy (IgAN) represents a pivotal moment for both the drug and the broader treatment landscape. IgAN is a chronic, progressive autoimmune disease that often leads to kidney failure, and while current treatments aim to manage symptoms, truly disease-modifying therapies that preserve kidney function are highly sought after. Voyxact, an APRIL inhibitor, had already received accelerated FDA approval based on its ability to reduce proteinuria, a surrogate marker of kidney damage.

However, the new data showing a stabilization, and even a slight increase, in estimated glomerular filtration rate (eGFR) – a direct measure of kidney function – is a game-changer. Patients on Voyxact experienced a 0.7 mL/min/1.73 m2 increase in eGFR at 12 months, starkly contrasting with a 4.8 mL/min/1.73 m2 decline in the placebo group. This not only meets the professional standard for slowing decline but suggests a potential to actively preserve kidney function, offering a tangible benefit that could delay or prevent the need for dialysis or transplant.

This robust eGFR data is critical for Otsuka to convert Voyxact's accelerated approval to full FDA approval, solidifying its position as a foundational therapy for IgAN. It also provides strong validation for the APRIL inhibition pathway, signaling to the scientific community and other developers that targeting this mechanism can yield significant clinical benefits beyond just proteinuria reduction. This could lead to a more competitive but ultimately more innovative IgAN treatment space. However, considerations remain regarding the long-term durability of these eGFR benefits and the full safety profile beyond the interim period. Furthermore, while the data is promising, the generalizability of the observed eGFR improvement across all patient subgroups will be important to understand as the drug moves towards broader clinical use. This development sets a new, higher bar for efficacy in IgAN, potentially reshaping future clinical development and patient care strategies.